First Trust Direct Indexing L.P. Increases Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

First Trust Direct Indexing L.P. boosted its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 10.8% during the 4th quarter, HoldingsChannel.com reports. The fund owned 1,778 shares of the specialty pharmaceutical company’s stock after buying an additional 173 shares during the period. First Trust Direct Indexing L.P.’s holdings in Jazz Pharmaceuticals were worth $219,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Covestor Ltd lifted its holdings in Jazz Pharmaceuticals by 676.5% in the third quarter. Covestor Ltd now owns 396 shares of the specialty pharmaceutical company’s stock valued at $51,000 after acquiring an additional 345 shares during the period. Spire Wealth Management boosted its holdings in shares of Jazz Pharmaceuticals by 128.6% during the 3rd quarter. Spire Wealth Management now owns 423 shares of the specialty pharmaceutical company’s stock valued at $55,000 after purchasing an additional 238 shares during the last quarter. Headinvest LLC purchased a new stake in shares of Jazz Pharmaceuticals in the third quarter worth about $56,000. Signaturefd LLC boosted its stake in Jazz Pharmaceuticals by 85.7% during the third quarter. Signaturefd LLC now owns 546 shares of the specialty pharmaceutical company’s stock valued at $71,000 after buying an additional 252 shares during the last quarter. Finally, Headlands Technologies LLC purchased a new position in Jazz Pharmaceuticals during the 3rd quarter valued at approximately $78,000. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Stock Performance

JAZZ stock opened at $110.70 on Thursday. Jazz Pharmaceuticals plc has a twelve month low of $103.01 and a twelve month high of $146.70. The firm has a market cap of $6.98 billion, a price-to-earnings ratio of 22.82, a PEG ratio of 1.53 and a beta of 0.63. The business’s fifty day simple moving average is $115.18 and its two-hundred day simple moving average is $120.55. The company has a quick ratio of 1.90, a current ratio of 2.27 and a debt-to-equity ratio of 1.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing the consensus estimate of $4.44 by ($0.04). The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1.01 billion. Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. Analysts predict that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current year.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 5,000 shares of the firm’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $109.65, for a total transaction of $548,250.00. Following the transaction, the executive vice president now directly owns 36,629 shares in the company, valued at approximately $4,016,369.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Jazz Pharmaceuticals news, CFO Philip L. Johnson bought 12,000 shares of the company’s stock in a transaction on Friday, March 1st. The shares were bought at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the acquisition, the chief financial officer now directly owns 27,932 shares in the company, valued at $3,342,063.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Neena M. Patil sold 5,000 shares of the firm’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $109.65, for a total transaction of $548,250.00. Following the transaction, the executive vice president now directly owns 36,629 shares in the company, valued at approximately $4,016,369.85. The disclosure for this sale can be found here. 4.40% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on JAZZ. Piper Sandler raised their target price on shares of Jazz Pharmaceuticals from $171.00 to $188.00 and gave the company an “overweight” rating in a report on Wednesday, March 20th. HC Wainwright reissued a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Friday, May 3rd. JPMorgan Chase & Co. upped their target price on shares of Jazz Pharmaceuticals from $170.00 to $190.00 and gave the company an “overweight” rating in a research report on Friday, March 22nd. UBS Group dropped their price target on Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating for the company in a research report on Friday, March 1st. Finally, StockNews.com downgraded Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 2nd. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $192.75.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.